Published in Int J Cancer on December 22, 1999
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer (2008) 1.76
MYC and Breast Cancer. Genes Cancer (2010) 1.66
MYC in breast tumor progression. Expert Rev Anticancer Ther (2008) 1.49
Targeting MYC-Regulated miRNAs to Combat Cancer. Genes Cancer (2010) 0.94
A prognostic index for operable, node-negative breast cancer. Br J Cancer (2004) 0.89
Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer. BMC Cancer (2006) 0.87
Prognostic value of p53 and bcl-2 expression in patients treated with breast conservative therapy. J Korean Med Sci (2010) 0.84
Role of Foxa1 in regulation of bcl2 expression during oxidative-stress-induced apoptosis in A549 type II pneumocytes. Cell Stress Chaperones (2009) 0.81
Prognostic significance of deregulated dicer expression in breast cancer. PLoS One (2013) 0.80
Effect Modification of Hormonal Therapy by p53 Status in Invasive Breast Cancer. J Breast Cancer (2013) 0.79
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A (1992) 3.27
Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A (1995) 2.56
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol (1996) 2.17
Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res (1985) 2.06
Prognostic importance of low c-erbB2 expression in breast tumors. J Natl Cancer Inst (1998) 2.00
Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Br J Cancer (1998) 1.96
Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol (2003) 1.96
Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg (1998) 1.79
Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol (2004) 1.79
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer (2001) 1.78
Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol (1989) 1.60
Complete nucleotide sequence of minicircle kinetoplast DNA from Trypanosoma equiperdum. Proc Natl Acad Sci U S A (1981) 1.56
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol (2005) 1.54
Electron microscopy of the circular kinetoplastic DNA from Trypanosoma cruzi: occurrence of catenated forms. Proc Natl Acad Sci U S A (1969) 1.49
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol (2014) 1.45
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol (1995) 1.36
Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer (1989) 1.35
Preparation and properties of nuclear and satellite deoxyribonucleic acid of Trypanosoma cruzi. J Mol Biol (1967) 1.31
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol (2007) 1.29
Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med (1988) 1.25
Replicating, convalently closed, circular DNA from kinetoplasts of Trypanosoma cruzi. Proc Natl Acad Sci U S A (1972) 1.23
The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer (2004) 1.22
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer (2003) 1.17
ATP-independent type II topoisomerase from trypanosomes. Proc Natl Acad Sci U S A (1986) 1.16
Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res (1988) 1.16
Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene (1990) 1.16
Extensive molecular screening for hereditary non-polyposis colorectal cancer. Br J Cancer (2000) 1.15
Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy. Radiology (1987) 1.15
Expression of miR-487b and miR-410 encoded by 14q32.31 locus is a prognostic marker in neuroblastoma. Br J Cancer (2011) 1.15
Retained surgical sponge or gossypiboma of the breast. Eur J Radiol (2002) 1.13
Purification and characterization of Plasmodium berghei DNA topoisomerases I and II: drug action, inhibition of decatenation and relaxation, and stimulation of DNA cleavage. Biochemistry (1986) 1.11
Breast elasticity: principles, technique, results: an update and overview of commercially available software. Eur J Radiol (2012) 1.10
Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst (1989) 1.08
C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet (1987) 1.08
Compliance with cotrimoxazole prophylaxis for the prevention of opportunistic infections in HIV-positive tuberculosis patients in Thyolo district, Malawi. Int J Tuberc Lung Dis (2001) 1.07
Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res (1989) 1.06
Absence of kinetoplast DNA in a late antigenic variant of Trypanosoma equiperdum. Mol Biochem Parasitol (1980) 1.06
Hepatectomy for liver metastases from breast cancer. Eur J Surg Oncol (1995) 1.05
Primary breast sarcoma: a review of 33 cases with immunohistochemistry and prognostic factors. Breast Cancer Res Treat (1989) 1.05
Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol (1986) 1.05
Abnormal circular DNA molecules induced by ethidium bromide in the kinetoplast of Trypanosoma cruzi. Proc Natl Acad Sci U S A (1969) 1.02
Conservative management of breast cancer. Br J Surg (1986) 1.00
A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer (2006) 1.00
[Fractionation and characterization of desoxyribonucleic acid (DNA) of trypanosomes (Trypanosoma equiperdum)]. C R Acad Sci Hebd Seances Acad Sci D (1966) 1.00
Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues. Cancer Res (1993) 0.99
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br J Cancer (1996) 0.99
Surgical and chemotherapeutic treatment of hepatic metastases from carcinoma of the breast. Surg Gynecol Obstet (1991) 0.98
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol (2008) 0.98
c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int J Cancer (2001) 0.98
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol (2007) 0.97
Occurrence of a kinetoplast DNA-protein complex in Trypanosoma cruzi. Biochem Biophys Res Commun (1981) 0.97
Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers. Oncogene (2000) 0.96
Chromatin reconstitution on small DNA rings. IV. DNA supercoiling and nucleosome sequence preference. J Mol Biol (1992) 0.96
Long-term effect of internal mammary chain treatment. Results of a multivariate analysis of 1195 patients with operable breast cancer and positive axillary nodes. Radiother Oncol (1988) 0.96
Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol (1994) 0.96
Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol (1995) 0.95
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol (2002) 0.95
Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. Eur J Cancer (2012) 0.95
[Induction of a "dyskinetoplast" by ethidium bromide in Trypanosoma cruzi cultivated in vitro]. C R Acad Sci Hebd Seances Acad Sci D (1967) 0.94
Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res (1991) 0.93
Coactivation of the MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in the nude mouse. Cancer Res (1994) 0.93
Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and expression in lymph node metastases of human head and neck carcinomas. Br J Cancer (1990) 0.93
[Neurosarcoma associated with Von Recklinghausen disease: apropos of 25 cases observed at the Gustave Roussy Institute from 1967 to 1990]. Bull Cancer (1992) 0.92
Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol (1992) 0.92
Transfer of Ku86 RNA antisense decreases the radioresistance of human fibroblasts. Cancer Gene Ther (2000) 0.91
Efficacy of adjuvant chemotherapy according to Prion protein expression in patients with estrogen receptor-negative breast cancer. Ann Oncol (2007) 0.91
[Study of kinetoplast DNA of Trypansoma cruzi using restriction endonucleases]. C R Acad Sci Hebd Seances Acad Sci D (1975) 0.90
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. Ann Oncol (2012) 0.90
c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer (1995) 0.90
Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'. Ann Oncol (2005) 0.90
ATP-independent DNA topoisomerase II as potential drug target in trypanosomes. Biol Cell (1988) 0.89
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol (1990) 0.89
Ultrastructural alterations of Trypanosoma cruzi kinetoplast induced by the interaction of a trypanocidal drug (hydroxystilbamidine) with the kinetoplast DNA. J Ultrastruct Res (1971) 0.89
Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. Ann Oncol (2002) 0.89
In vivo stimulation by antitumor drugs of the topoisomerase II induced cleavage sites in c-myc protooncogene. Biochem Biophys Res Commun (1986) 0.89
A type I DNA topoisomerase from Trypanosoma cruzi. Eur J Biochem (1983) 0.89
Molecular organization of the kinetoplast DNA of Trypanosoma cruzi treated with berenil, a DNA interacting drug. J Ultrastruct Res (1972) 0.89
A before-after study using OncoDoc, a guideline-based decision support-system on breast cancer management: impact upon physician prescribing behaviour. Stud Health Technol Inform (2001) 0.88
[DNA ultrastructure of the kinetoplast of Trypanosoma cruzi cultivated in vitro]. C R Acad Sci Hebd Seances Acad Sci D (1969) 0.88
[Presence of papillomavirus genomes and amplification of the c-myc and C-Ha-ras oncogenes in invasive cancers of the uterine cervix]. C R Acad Sci III (1984) 0.88
Circular oligomers in mitochondrial DNA of human and beef nonmalignant thyroid glands. Proc Natl Acad Sci U S A (1972) 0.88
Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. Ann Oncol (2008) 0.87
Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochem Pharmacol (1993) 0.87
Structure and expression of c-myc and c-fos proto-oncogenes in thyroid carcinomas. Br J Cancer (1988) 0.86
Prognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix. J Clin Oncol (1990) 0.86